1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Qingdao Vland Biotech Inc.

Qingdao Vland Biotech Inc.

603739.SS
Qingdao Vland Biotech Inc.CN flagShanghai Stock Exchange
11.85
CNY
+0.14
- -
3.00BMarket Cap
Qingdao Vland Biotech Inc.
603739.SS
(Shanghai Stock Exchange)

Recent

price

11.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.49
4.66
4.8
4.94
5.02
3.97
4.23
4.69
4.66
4.75
5.27
5.48
5.7
Revenue per Share
0.33
0.44
0.51
0.53
0.51
0.36
0.48
0.54
0.28
0.32
0.25
0.28
0.25
Basic EPS, GAAP
0.05
0.12
0.79
0.39
0.09
-0.26
-0.17
-1.65
-0.99
-0.25
0.36
0.14
-0.35
Free Cash Flow per Basic Share
0.32
0.17
0.33
0.37
0.38
0.15
0.14
0.15
0.21
0.16
0.22
0.17
0.22
Dividend per Share
2.61
2.9
3.04
3.18
3.3
2.9
3.02
3.58
3.64
3.79
3.97
4.15
4.16
Book Value per Share
2.42
2.66
2.94
3.13
3.36
4.44
4.33
6.25
6.33
6.35
6.6
6.82
6.88
Tangible Book Value per Share
162
161
163
162
162
213
227
246
249
252
251
249
239
Basic Weighted Avg Shares
728
752
781
799
814
847
960
1,151
1,163
1,199
1,321
1,366
1,364
Sales/Revenue/Turnover
9.2
10.31
13.9
14.99
14.22
11.06
15.59
15.3
10.78
11.79
11.07
9.81
10.7
Operating Margin (%)
32
34
34
35
36
38
43
52
66
74
111
117
- -
Depreciation Expense
53
70
83
86
83
78
109
133
70
81
63
70
60
Net Income, GAAP
24.86
20.64
21.49
21.06
16.82
8.42
12.73
12.43
16.42
16.03
25.33
21.21
26.04
Effective Tax Rate (%)
7.31
9.35
10.57
10.71
10.24
9.18
11.35
11.52
6
6.73
4.74
5.11
4.4
Profit Margin (%)
167
168
205
213
211
522
469
599
324
36
38
172
21
Working Capital
30
15
- -
3
2
7
- -
99
149
62
14
60
7
LT Debt
466
519
558
593
632
1,032
1,115
1,686
1,734
1,825
1,870
1,911
1,859
Total Equity
- -
9.98
13.9
14.93
13.81
9.6
11.77
10.07
5.06
5
4.4
4.23
4.24
Return on Invested Capital (%)
- -
11.47
13.58
13.38
11.52
9.46
12.41
11.51
4.44
4.3
2.78
3.13
2.47
Return on Capital (%)
- -
15.79
17.17
16.96
15.88
13.49
16.71
16.94
7.81
8.65
6.42
6.89
6.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
622
683
632
LT Borrowings
14
26
7
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
253
253
253
Market Capitalization
3,051
3,038
3,189

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,069
1,102
1,038
Cash, Cash Equivalents & STI
448
472
350
Accounts Receivable, Net
350
354
379
Inventories
189
194
224
Total Current Liabilities
1,031
1,057
1,017
Payables & Accruals
- -
- -
- -
ST Debt
622
683
632
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.56%
12.78%
2.18%
Free Cash Flow
44.94%
103.61%
-62.58%
Net Income, GAAP
3.09%
-4.21%
11.45%
Sales/Revenue/Turnover
6.31%
7.52%
3.43%
Total Cash Common Dividend
10.92%
9.57%
-22.13%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
287
322
336
375
1,321
2025
310
342
350
- -
1,366
2026
345
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
0.25
2025
0.04
- -
- -
- -
0.28
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.22
2025
0.02
- -
- -
- -
0.17
2026
0.01
- -
- -
- -
- -
Similar Companies
ForU Holdings, Inc. (FORU)
Mabion S.A. (MAB.WA)
Kinnate Biopharma Inc. (KNTE)
NeoImmuneTech, Inc. (950220.KQ)
Inventiva S.A. (IVEVF)
Sienna Biopharmaceuticals, Inc. (SNNAQ)
Business
Qingdao Vland Biotech Inc. (603739.SS) engages in the research, development, production and sale of enzyme preparations, microecological preparations, animal health products and marine aquaculture solutions principally in China and internationally. The company offers a broad portfolio of products including feed enzymes, industrial enzymes and food enzymes; probiotics such as aquaculture premixes, health products, animal probiotics and plant probiotics; animal vaccines and biological products encompassing live and inactivated poultry and swine vaccines as well as egg yolk antibodies; poultry drugs comprising antiparasitic, antiviral and nutritional drugs together with disinfectants; and traditional Chinese veterinary medicines for livestock, scale, avian breeding and laying hens. It operates across industries such as agriculture, animal husbandry, textile, pulp and paper, health care, laundry, biofuel, household cleaning, detergents, food, animal feed, environmental protection and washing. Founded in 2005 and headquartered at Vland Innovation Park, No. 596-1 Jiushui East Road, Laoshan District, Qingdao, Shandong, China, the company maintains 33 subsidiary companies, nine production bases and nine technology centers with over 1,500 employees worldwide. Qingdao Vland Biotech Inc. listed on the Shanghai Stock Exchange A-shares main board in 2019. Recent developments include the January 2024 operational launch of Evonik Vland Biotech (Shandong) Co., Ltd., a joint venture with Evonik based in Qingdao and utilizing production facilities in Huimin to expand market presence with probiotics and solutions for livestock gut health, complemented by Evonik's distribution outside Greater China. The company established Vland Biotechnology Ho Chi Minh Company Limited in Vietnam in 2018 and the Vland-ADM Joint Enzyme R&D Center in California, US, in 2017, while forming an ADM joint venture in 2021 to address growing Chinese demand for human probiotics; in 2022, it created ADM-Vland Biotech (Shandong) Co., Ltd.